Recurrent Melanoma Withdrawn Phase 1 Trials for Vemurafenib (DB08881)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Withdrawn1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02145910Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain MetastasesTreatment